1.Lower bile duct stenosis caused by xanthogranulomatous cholangitis complicated with jaundice.
Jun MA ; Hua FAN ; Ping WEI ; Jian-tao KOU ; Qiang HE
Chinese Medical Journal 2013;126(23):4600-4600
Aged
;
Bile Ducts
;
pathology
;
Cholangitis
;
complications
;
Humans
;
Jaundice
;
complications
;
Male
2.Drug-induced bile duct injury: progress and challenges.
Chinese Journal of Hepatology 2023;31(4):339-344
Drug-induced bile duct injury is a specific kind of drug-induced liver injury that has two main pathological types, namely ductopenia, or vanishing bile duct syndrome, and secondary sclerosing cholangitis. However, in recent years, the reports of new drugs that cause bile duct injury have been constantly increasing, and these drugs have different clinicopathological features and a novel pathogenesis. Therefore, this paper summarizes and analyzes the progress and challenges in the etiology, pathogenesis, diagnosis and treatment, and other aspects of drug-induced bile duct injury.
Humans
;
Cholestasis/chemically induced*
;
Cholangitis, Sclerosing/diagnosis*
;
Chemical and Drug Induced Liver Injury/pathology*
;
Bile Ducts/pathology*
3.Negative conversion of antimitochondrial antibody in primary biliary cirrhosis: a case of autoimmune cholangitis.
Yun Ju CHO ; Dong Soo HAN ; Think You KIM ; Se Jin JANG ; Yong Chul JEON ; Joo Hyun SOHN ; In Hong LEE ; Kyung Nam PARK
Journal of Korean Medical Science 1999;14(1):102-106
Autoimmune cholangitis is a clinical constellation of chronic cholestasis, histological changes of chronic nonsuppurative cholangitis and the presence of autoantibodies other than antimitochondrial antibody (AMA). It is uncertain whether this entity is definitely different from AMA positive primary biliary cirrhosis (PBC), though it shows some differences. We report a case of autoimmune cholangitis in a 59-year-old woman, who had been previously diagnosed as AMA-positive PBC associated with rheumatoid arthritis, has been converted to an AMA-negative and anticentromere antibody-positive PBC during follow-up. The response to ursodeoxycholic acid treatment is poor except within the first few months, but prednisolone was dropping the biochemical laboratory data.
Autoantibodies/immunology*
;
Case Report
;
Cholangitis/pathology
;
Cholangitis/immunology*
;
Female
;
Human
;
Liver Cirrhosis, Biliary/pathology
;
Liver Cirrhosis, Biliary/immunology*
;
Middle Age
;
Mitochondria/immunology*
4.Primary Sclerosing Cholangitis.
The Korean Journal of Hepatology 2004;10(2):154-157
No abstract available.
Adult
;
Cholangitis, Sclerosing/*diagnosis/pathology
;
Diagnosis, Differential
;
Humans
;
Liver Cirrhosis, Biliary/diagnosis
;
Male
5.Clinical and pathological features of 27 cases of primary sclerosing cholangitis.
Xin-yan ZHAO ; Wan-wei WANG ; Xiao-juan OU ; Tai-ling WANG ; Ji-dong JIA
Chinese Journal of Hepatology 2010;18(9):685-688
OBJECTIVETo elucidate clinical and pathological features of primary sclerosing cholangitis (PSC) in order to improve clinician's awareness of this rare disease.
METHODSWe retrospectively analyzed clinical data and follow-up information of 27 PSC patients who were admitted to Beijing Friendship Hospital from January 1990 to November 2009. The patients were classified into classic PSC and small-duct PSC according to biochemistry and imaging results. After 3 to 6 months of therapy, those patients with serum ALT < or = 1.5, TBil < or = 2 and ALP < or = 2.5 ULN were determined as good responders. The treatment results between the two groups were compared.
RESULTS9 out of 27 cases of PSC were small duct PSC and 18 cases were large bile duct or classic PSC. Male patients (7) were less than females (20) and the average age was 47.6 years. Main clinical symptoms included jaundice (85.2%), pruritis (48.1%),fatigue (68.4 %), abdominal pain (40.7%) and fever (14.8%), main physical sign included hepatomegaly (44.4%), splenomegaly (48.1 %) and ascites (14.8%). Laboratory features included elevated IgG (81.8%), positive ANA (69.6%) and pANCA (52.9%). 22% of these PSC patients had ulcerative colitis or Sjogren's syndrome. A small percentage of patients were responsive to standard therapy, of which small duct PSC had a better response than classic PSC (66.7 % vs 33.3%, P = 0.041).
CONCLUSIONSUlcerative colitis (22.2%) is not as common as reported by western countries. Small duct PSC has a better treatment response. Searching of effective treatment regimen for large bile duct PSC is warranted in future studies.
Adolescent ; Adult ; Aged ; Cholangitis, Sclerosing ; pathology ; therapy ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Young Adult
7.Pathologic diagnosis of autoimmune liver disease.
Chinese Journal of Pathology 2007;36(11):772-776
Autoimmune Diseases
;
drug therapy
;
pathology
;
Cholangitis
;
drug therapy
;
immunology
;
pathology
;
Cholangitis, Sclerosing
;
drug therapy
;
immunology
;
pathology
;
Hepatitis, Autoimmune
;
drug therapy
;
immunology
;
pathology
;
Humans
;
Interferon-gamma
;
therapeutic use
;
Liver Cirrhosis, Biliary
;
drug therapy
;
immunology
;
pathology
;
Ursodeoxycholic Acid
;
therapeutic use
8.IgG4-related sclerosing cholangitis: liver biopsy findings.
The Korean Journal of Hepatology 2011;17(1):76-79
No abstract available.
Aged
;
Biopsy, Fine-Needle
;
Cholangitis, Sclerosing/*pathology/ultrasonography
;
Humans
;
Immunoglobulin G/*blood
;
Liver/*pathology
;
Male
;
Tomography, X-Ray Computed
10.Recent Advances in the Management of Recurrent Bile Duct Stones.
The Korean Journal of Gastroenterology 2015;66(5):251-254
Approximately 3-15% of patients who have undergone removal of bile duct stones with endoscopic sphincterotomy have recurrence of stones which often presents as acute cholangitis. Despite better understanding on the factors and mechanisms underlying the recurrence of bile duct stones achieved during the past few decades, endoscopic removal still remains the mainstay of management for recurrent bile duct stones. Recently investigated and suggested management of recurrent bile duct stones are highlighted in this review.
Cholangiopancreatography, Endoscopic Retrograde
;
Cholangitis/pathology
;
Gallstones/surgery/*therapy
;
Humans
;
Recurrence
;
Risk Factors
;
Sphincterotomy, Endoscopic
;
Ursodeoxycholic Acid/administration & dosage